(CGDV) Capital Dividend Value - Overview
Etf: Large-Cap Dividend Stocks
| Risk 5d forecast | |
|---|---|
| Volatility | 11.3% |
| Relative Tail Risk | 0.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.15 |
| Alpha | 12.09 |
| Character TTM | |
|---|---|
| Beta | 0.818 |
| Beta Downside | 0.848 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.28% |
| CAGR/Max DD | 1.78 |
Description: CGDV Capital Dividend Value February 11, 2026
CGDV is a U.S.-focused, large-value ETF that commits at least 80% of its net assets to dividend-paying common stocks of established companies with market capitalizations above $4 billion, while allowing up-to-10% exposure to similar large-cap equities outside the United States. The fund is classified as non-diversified, meaning it may hold fewer than 40 securities, which can amplify both upside and downside risk.
As of the most recent quarterly filing (30 Sept 2024), CGDV reported an expense ratio of 0.45% and a trailing 12-month dividend yield of approximately 3.2%, slightly above the S&P 500 average of 1.7%. Its top five holdings-Microsoft (MSFT), Johnson & Johnson (JNJ), JPMorgan Chase (JPM), Procter & Gamble (PG), and Verizon (VZ)-account for roughly 28% of assets, reflecting a concentration in technology, healthcare, financials, consumer staples, and communications services. The fund’s performance has been positively correlated (≈0.78) with the U.S. large-cap value index, benefitting from a recent rotation toward value stocks as the Federal Reserve signals a pause in rate hikes.
For a deeper dive into how CGDV’s dividend-focused strategy aligns with broader macro trends, you might explore ValueRay’s analytical tools to model scenario-based outcomes.
Altman Z''
Beneish M
| DSRI: none (Receivables none/none, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: none (NI 0.0 - CFO 0.0) / TA none) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of CGDV shares?
Over the past week, the price has changed by -0.24%, over one month by +4.38%, over three months by +8.05% and over the past year by +24.16%.
Is CGDV a buy, sell or hold?
What are the forecasts/targets for the CGDV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
CGDV Fundamental Data Overview February 18, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 29.84b USD (29.84b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 29.84b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 29.84b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.93% (E(29.84b)/V(29.84b) * Re(8.93%) + (debt-free company))
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)